Abstract

ABSTRACTB lymphocytes are important players in immune responses to cancer. However, their composition and function in head and neck squamous cell carcinoma (HNSCC) has not been well described. Here, we analyzed B cell subsets in HNSCC (n = 38), non-cancerous mucosa (n = 14) and peripheral blood from HNSCC patients (n = 38) and healthy controls (n = 20) by flow cytometry. Intratumoral B cells contained high percentages of activated (CD86+), antigen-presenting (CD86+/CD21−) and memory B cells (IgD−/CD27+). T follicular helper cells (CD4+/CXCR5+/CD45RA−/CCR7−) as key components of tertiary lymphoid structures and plasma cells made up high percentages of the lymphocyte infiltrate. Percentages of regulatory B cell varied depending on the regulatory phenotype. Analysis of humoral immune responses against 23 tumor-associated antigens (TAA) showed reactivity against at least one antigen in 56% of HNSCC patients. Reactivity was less frequent in human papillomavirus associated (HPV+) patients and healthy controls compared to HPV negative (HPV−) HNSCC. Likewise, patients with early stage HNSCC or MHC-I loss on tumor cells had low TAA responses. Patients with TAA responses showed CD4+ dominated T cell infiltration compared to mainly CD8+ T cells in tumors without detected TAA response. To summarize, our data demonstrates different immune infiltration patterns in relation to serological TAA response detection and the presence of B cell subpopulations in HNSCC that can engage in tumor promoting and antitumor activity. In view of increasing use of immunotherapeutic approaches, it will be important to include B cells into comprehensive phenotypic and functional analyses of tumor-associated lymphocytes.

Highlights

  • The immune system plays an important role in anticancer activity on one side and cancer development and progression on the other side

  • CD45+ lymphocytes and CD19+/CD20+ B cells are increased in human papillomaviruses (HPV)+ head and neck squamous cell carcinoma (HNSCC)

  • The gating strategy for B cell subsets is outlined in an exemplary tumor containing high percentages of CD19+/CD20+ cells (Figure 1A)

Read more

Summary

Introduction

The immune system plays an important role in anticancer activity on one side and cancer development and progression on the other side. Regulatory T cells have been described in various cancer entities including head and neck squamous cell carcinoma (HNSCC) as major contributors to immune evasion.[1,2] In contrast, CD8+ T cells are a main anticancer effector cell subset in HNSCC. Their function is often hampered by overexpression of immune checkpoint molecules such as programmed cell death protein 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).[3] These molecules have become targets of immunotherapeutic approaches that are changing the landscape of cancer therapy. PD-1 inhibitors have shown substantial activity in recurrent/ metastatic HNSCC.[4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call